11.17 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||10.27 x 500|
|Ask||11.70 x 1000|
|Day's Range||10.91 - 11.32|
|52 Week Range||10.04 - 39.90|
|PE Ratio (TTM)||0.32|
|Earnings Date||Feb 27, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||14.50|
CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:00 a.m. PT in San Francisco. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.
Merrimack (MACK) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMBRIDGE, Mass., Nov. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced the addition of George Demetri, M.D., a professor of medicine at Harvard Medical School and physician-scientist faculty member at the Dana-Farber Cancer Institute (DFCI), to its Board of Directors. Dr. Demetri, a world-renowned expert in the clinical translation of innovative treatment strategies for cancer, replaces John Mendelsohn, M.D., who is retiring from the Board.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) outperformed the Biotechnology industry on the basis of its ROE – producing a higher 175.74% relative to the peer average of 16.08% over the past 12Read More...
CAMBRIDGE, Mass., Nov. 14, 2017 /PRNewswire/ -- Torque, an immuno-oncology company developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor microenvironment, today announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering. The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the "hostile" tumor microenvironment, without systemic exposure.
Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
The Cambridge, Massachusetts-based company said it had net income of 24 cents per share. Losses, adjusted to account for discontinued operations, were 40 cents per share. The results topped Wall Street ...
Merrimack Pharmaceuticals (MACK) announced third quarter results with loss narrower than expected, however, revenues misses the same.
- Received orphan drug designation for MM-121 in heregulin positive non-small cell lung cancer - - Resolved convertible note litigation associated with asset sale to Ipsen S.A. and commenced tender offer ...
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 ...
Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that indoximod, its investigational drug candidate, was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of heregulin positive non-small cell lung cancer. "This is an important regulatory step forward for the clinical development of MM-121 in non-small cell lung cancer and we are pleased to have access to additional support from the FDA in this indication," said Sergio Santillana, M.D., MSc, Chief Medical Officer.
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
CAMBRIDGE, Mass. , Oct. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, ...
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
ISIN No. US590328AA86) (the "Notes"), which amount reflects the consummation of the purchase of the Notes from the Settlement Noteholders (as defined herein) pursuant to the Settlement Agreement (as defined herein). The Company agreed to conduct the Tender Offer in connection with the settlement agreement (the "Settlement Agreement") that it entered into on October 6, 2017 with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, the "Settlement Noteholders") and Wells Fargo Bank, National Association (the "Trustee") to resolve the lawsuit pending in the Court of Chancery in the State of Delaware captioned Wells Fargo Bank, N.A., et al. v. Merrimack Pharmaceuticals, Inc., C.A. No. 2017-0199-JTL filed by the Settlement Noteholders and the Trustee.
If you are a shareholder in Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has reached a settlement agreement with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, "Noteholder Plaintiffs") and Wells Fargo Bank, National Association, to resolve the previously disclosed lawsuit captioned Wells Fargo Bank, N.A., et. al. v. Merrimack Pharmaceuticals, Inc. pending in the Court of Chancery in the State of Delaware (the "Delaware Action").
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...
NEW YORK, NY / ACCESSWIRE / September 7, 2017 / After posting the worst daily drop in weeks on rising geopolitical tensions between North Korea and the from their worst daily drop in weeks, U.S. markets ...
Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.
CAMBRIDGE, Mass., Aug. 31, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that the previously disclosed one-for-ten reverse stock split of its issued and outstanding common stock will be effective for trading purposes as of the commencement of trading on September 6, 2017. Merrimack's stockholders approved an amendment to the Company's certificate of incorporation to effect the reverse stock split at the Annual Meeting of Stockholders on August 11, 2017.
CAMBRIDGE, Mass., Aug. 14, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has strengthened its executive management team with the appointment of Jean M. Franchi as Chief Financial Officer, effective August 21, 2017. In this role, Ms. Franchi will plan and oversee Merrimack's financial strategy to support the ongoing development of multiple clinical- and preclinical-stage product candidates for cancer. Over the course of a 30-year career in the biotechnology and life sciences sectors, Ms. Franchi has held senior financial management roles at several leading companies spanning all stages of development, from research to commercial.